Krystal Biotech, Inc. financials

KRYS CIK 0001711279

Source: EDGAR filings · Built 2026-06-02T03:25:00Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2021FY 2021FY 2020
Free Cash Flow 188.91M 119.18M -100.60M -153.55M -116.27M -40.93M
EBITDA 167.02M 71.72M -104.61M -141.14M -65.51M -31.15M
Working Capital 921.66M 640.05M 554.82M 354.93M 416.53M 259.61M
Net Debt -486.96M -337.60M -350.23M -152.97M -333.22M -264.32M
Operating Margin 41.45% 22.63% -216.21%
Net Margin 52.64% 30.69% 21.56%
Return on Equity (ROE) 16.80% 9.42% 1.40% -26.80% -11.72% -11.01%
Return on Assets (ROA) 15.36% 8.44% 1.34% -25.06% -11.11% -10.35%
Current Ratio 9.95× 7.28× 17.76× 13.30× 17.18× 17.80×
Debt-to-Equity 0.01× 0.01× 0.01× 0.02× 0.01× 0.01×
Effective Tax Rate -8.11% 6.50% 15.24% 0.00% 0.00%
Cash Conversion Ratio 0.98× 1.38× -8.12× 0.72× 0.69× 0.81×
Accruals Ratio 0.00× -0.03× 0.12× -0.07× -0.03× -0.02×
SBC % of Revenue 14.01% 16.91% 78.76%
CapEx Coverage 16.81× 29.12× -7.53× -1.90× -0.70× -1.76×
Free Cash Flow Per Share $6.31 $4.01 $-3.63 $-6.02 $-5.24 $-2.18

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2021FY 2021FY 2020
P/E Trailing (Diluted) 36.04× 52.22× 318.10×
P/FCF 39.09× 39.09×
FCF Yield 2.56% 2.56%
EV / EBITDA 40.18× 58.19×
P/S 18.50× 15.53× 69.10×
P/B 5.90× 4.77× 4.50× 3.91× 2.97× 4.05×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2021FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 389.13M 290.51M 50.70M 0 0
Research and Development Expense 58.05M 53.58M 46.43M 42.46M 27.88M 17.94M
Selling, General and Administrative Expense 146.74M 113.63M 98.29M 77.73M
Operating Expenses 227.84M 224.77M 160.32M 145.20M 68.28M 33.00M
Operating Income (Loss) 161.29M 65.75M -109.62M -145.20M -68.28M -33.00M
Income Tax Expense (Benefit) -15.36M 6.20M 1.97M 0 0 0
Net Income (Loss) Attributable to Parent 204.83M 89.16M 10.93M -139.97M -69.57M -32.17M
Earnings Per Share, Basic $7.08 $3.12 $0.40 $-5.49 $-3.13 $-1.71
Weighted Average Number of Shares Outstanding, Basic 28.94M 28.59M 27.15M 25.49M 22.20M 18.79M
Earnings Per Share, Diluted $6.84 $3.00 $0.39 $-5.49 $-3.13 $-1.71
Weighted Average Number of Shares Outstanding, Diluted 29.95M 29.74M 27.75M 25.49M 22.20M 18.79M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2021FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 496.30M 344.87M 358.33M 161.90M 341.25M 268.27M
Assets, Current 1.02B 742.04M 587.91M 383.78M 442.27M 275.06M
Assets 1.33B 1.06B 818.36M 558.45M 626.29M 310.84M
Liabilities, Current 102.94M 102.00M 33.09M 28.85M 25.74M 15.45M
Liabilities 114.23M 109.46M 39.71M 36.22M 32.72M 18.76M
Stockholders' Equity Attributable to Parent 1.22B 946.38M 778.64M 522.23M 593.58M 292.08M
Common Stock, Shares, Outstanding 29.19M 28.79M 28.24M 25.76M 25.21M 19.71M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2021FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 200.87M 123.42M -88.80M -100.57M -47.94M -26.08M
Payments to Acquire Property, Plant, and Equipment 11.95M 4.24M 11.80M 52.98M 68.34M 14.84M
Net Cash Provided by (Used in) Investing Activities -58.42M -163.44M 82.64M -114.08M -226.77M -11.18M
Net Cash Provided by (Used in) Financing Activities 8.71M 27.01M 202.75M 35.35M 347.69M 118.02M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (KRYS CIK 0001711279), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

CSBR

CHAMPIONS ONCOLOGY, INC.

MEDP

Medpace Holdings, Inc.

TT

TRANE TECHNOLOGIES PLC